The Drug Regulatory Authority of Pakistan has rejected reports of a recent increase in the prices of essential medicines, terming such claims baseless. A DRAP spokesperson clarified that there has been no hike in the prices of insulin and other life-saving drugs, adding that pharmaceutical companies are not allowed to raise prices independently.

A key reason for this stance is that Pakistan leads regional push to ease Middle East tensions, with officials noting that around 85 per cent of medicines used in the country are produced locally. Despite prevailing challenges and potential disruptions in supply routes, the availability of medicines remains stable.

Industry representatives have also indicated that there is no immediate risk of a shortage, with most companies maintaining sufficient stocks of raw materials and finished products to meet demand for the next four to six months. Earlier, the Competition Commission of Pakistan and DRAP signed a memorandum of understanding to strengthen cooperation.

Under the agreement, both institutions will share data and collaborate on policy research, regulatory oversight, and capacity-building initiatives. A comprehensive framework is also being developed to ensure effective monitoring of medicine prices and availability nationwide.

A DRAP spokesperson stated that steps are being taken to ensure the uninterrupted supply of medicines across Pakistan, including issuing key advisories to pharmaceutical companies directing them to diversify sources for the procurement of raw materials.